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ARTICLE OPEN
Deconstructing the traditional Japanese medicine “Kampo”:
compounds, metabolites and pharmacological proﬁle of
maoto, a remedy for ﬂu-like symptoms
Akinori Nishi1, Katsuya Ohbuchi1, Hirotaka Kushida1, Takashi Matsumoto1, Keiko Lee2, Haruo Kuroki3, Shigeki Nabeshima4,
Chika Shimobori1, Nagisa Komokata1, Hitomi Kanno1, Naoko Tsuchiya1, Makoto Zushi5, Tomohisa Hattori1, Masahiro Yamamoto1,
Yoshio Kase1, Yukiko Matsuoka 6 and Hiroaki Kitano6,7,8,9
Pharmacological activities of the traditional Japanese herbal medicine (Kampo) are putatively mediated by complex interactions
between multiple herbal compounds and host factors, which are difﬁcult to characterize via the reductive approach of purifying
major bioactive compounds and elucidating their mechanisms by conventional pharmacology. Here, we performed comprehensive
compound, pharmacological and metabolomic analyses of maoto, a pharmaceutical-grade Kampo prescribed for ﬂu-like symptoms,
in normal and polyI:C-injected rats, the latter suffering from acute inﬂammation via Toll-like receptor 3 activation. In total, 352
chemical composition-determined compounds (CCDs) were detected in maoto extract by mass spectrometric analysis. After maoto
treatment, 113 CCDs were newly detected in rat plasma. Of these CCDs, 19 were present in maoto extract, while 94 were presumed
to be metabolites generated from maoto compounds or endogenous substances such as phospholipids. At the phenotypic level,
maoto ameliorated the polyI:C-induced decrease in locomotor activity and body weight; however, body weight was not affected by
individual maoto components in isolation. In accordance with symptom relief, maoto suppressed TNF-α and IL-1β, increased IL-10,
and altered endogenous metabolites related to sympathetic activation and energy expenditure. Furthermore, maoto decreased
inﬂammatory prostaglandins and leukotrienes, and increased anti-inﬂammatory eicosapentaenoic acid and hydroxyl-
eicosapentaenoic acids, suggesting that it has differential effects on eicosanoid metabolic pathways involving cyclooxygenases,
lipoxygenases and cytochrome P450s. Collectively, these data indicate that extensive proﬁling of compounds, metabolites and
pharmacological phenotypes is essential for elucidating the mechanisms of herbal medicines, whose vast array of constituents
induce a wide range of changes in xenobiotic and endogenous metabolism.
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INTRODUCTION
Traditional herbal medicine (THM) is widely accepted and used
throughout the world, especially in Asia. Although there is
diversity among THMs, such as traditional Chinese medicine,
Tibetan medicine, Indian Ayurveda, and Japanese Kampo medi-
cine, they are empirically formulated and generally acknowledged
to work for certain cases.
Among various herbal remedies in the world, Kampo is unique
as a therapeutic agent that has been modernized through
technological and manufacturing innovation. Furthermore, Kampo
is covered by the national health insurance scheme and is
manufactured in accordance with both good manufacturing
practice (GMP) stipulated by Japanese law and Kampo GMP
guidelines1 to ensure stringent quality control at all stages of
production—a key element that is pivotal for the reproducibility
and standardization of biological effects, as well as for rigorous
scientiﬁc investigation.
Maoto, a pharmaceutical grade Kampo (TSUMURA Maoto
Extract Granules, TJ-27; Ma Huang Tang in Chinese) prepared
from a mixture of four component herbs, Armeniacae semen (AS)
(32.3%), Glycyrrhizae radix (GR) (9.6%), Cinnamomi cortex (CC)
(25.8%), and Ephedrae herba (EH) (32.3%), is prescribed widely to
treat symptoms of upper respiratory infections and inﬂuenza.
Clinical studies have shown that maoto has antipyretic2,3 and anti-
malaise effects4 in children, and improves ﬂu symptoms with
efﬁcacy comparable to that of neuraminidase inhibitors in adults
infected with inﬂuenza A virus.5,6 Experimentally, maoto has been
shown to decrease viral titer, while exerting an antipyretic effect.7
Furthermore, the herbal compounds in maoto have been reported
to have various modulating effects on the host’s immune system,
including Toll-like receptors (TLR)8–14 and a direct inhibitory effect
on viral growth.15–19 However, the mechanism of action of maoto
in acute infectious disorders is largely unclariﬁed due to the
presence of large and diverse compounds.
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Many THMs are considered to function through the synergetic
effects of the combined herbs; in other words, multiple active
compounds exert multifaceted inﬂuences on the body. Under-
standing which compounds are involved in this process and how
they give rise to synergetic effects are two major questions that
must be answered to understand THM.
To approach these questions, we need to address the complex
features of THM, step by step, with newly developed methodol-
ogies suitable for analyzing the multiple effects of such medicines.
As a ﬁrst step, it is important to characterize comprehensively the
compound proﬁle in the body after treatment with THM, mainly
by mass spectrometric analyses. Notably in THM, many com-
pounds present in the raw herbs are metabolized and converted
by the host xenobiotic system and gut microbial ﬂora. In order to
identify the actual compounds involved in THM efﬁcacy, it is
necessary to identify compounds that are present in the blood
after THM administration, as well as those present in the herbal
extract. Therefore, exhaustive measurements of THM-derived
compounds in both extracts and plasma are necessary. Further-
more, because THM contains numerous bioactive compounds that
are thought to have a deep and wide-ranging impact on host
metabolism, THM-induced changes in host metabolites are likely
to exert profound inﬂuences on human health and disease.
Metabolomic analysis on tissue samples of THM-treated humans,
both healthy and diseased, is therefore is indispensable in
understanding the mode of action of THM, which is essentially
different from that of Western medicines based on a single
compound.
In the present study, we have taken an integrated approach of
pharmacokinetics (PK) and metabolomics to investigate the effect
of the Japanese Kampo maoto on host immune response in acute
viral infection. We used a rat model of immune activation induced
by a viral mimic, polyinosinic–polycytidylic acid (poly I:C), which is
an agonist of TLR3 and causes fever, fatigue (decreased locomotor
activity), reduced food intake, body weight loss and inﬂammatory
cytokine surge, all of which reﬂect systemic symptoms or
phenotypes in patients with inﬂuenza-like illness.20,21 Using this
model, we performed metabolomic analyses of both maoto drug
extract and plasma after maoto administration in normal and
diseased rats, and evaluated the pharmacological effects on
disease symptoms, accompanied by an authentic PK study. This
approach has enabled comprehensive proﬁling of the changes in
maoto-derived compounds, endogenous metabolites, and inﬂam-
matory/symptomatic responses in the host, providing an inte-
grated picture of the biological impact of maoto on the body.
RESULTS
The workﬂow of this study is presented in Fig. 1. In a series of
analyses, maoto extract and rat plasma after maoto administration
were analyzed by liquid chromatography–Orbitrap-mass spectro-
metry (LC-Orbitrap-MS) to compare the differences in compound
proﬁle. The PK parameters of major compounds in maoto were
Fig. 1 Schematic view of the workﬂow in this study. a1 Pharmacokinetics analysis of major compounds was performed. Original compounds
in maoto, and their metabolites in plasma after maoto administration were measured by non-targeted and targeted analysis. a2
Pharmacological analysis of the effect of maoto on ﬂu-like symptoms was performed by conventional pharmacology and targeted
metabolome analysis. b1 MS peaks were annotated to determine the compounds, and the data for compounds originating from maoto, and
endogenous metabolites affected by maoto administration were summarized. b2 Common metabolites and lipid mediators affected by
maoto administration were summarized. c To integrate the obtained data, the detected compounds and metabolites were categorized and
pathway maps were built and annotated by literature and database knowledge curation
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measured by LC-MS/MS in plasma after maoto administration to
rat (Supplementary Table 1). The effects of maoto on polyI:C-
induced ﬂu-like symptoms, such as decreased locomotor activity
and body weight, and inﬂammatory cytokine response were
evaluated. Metabolomic changes in primary metabolites and lipid
mediators were analyzed in rat plasma by gas chromatography
(GC)-MS/MS and LC-MS/MS after maoto and polyI:C treatment. The
compounds and metabolites detected in these analyses were
categorized and built into pathway maps, and their functions were
annotated by literature/database curation. Lastly, the integrated
analysis enabled us to summarize the mode of action of maoto.
The summarized data are shown in Supplementary Fig. 1.
Compound and pharmacological proﬁling of maoto
A Nishi et al.
3
Published in partnership with the Systems Biology Institute npj Systems Biology and Applications (2017)  32 
Compound and metabolite proﬁling by LC-Orbitrap-MS analysis
after administration of maoto
LC-Orbitrap-MS analysis of compounds and metabolites in maoto
extract and in rat plasma at 1 and 8 h after oral administration was
performed. The combined results are summarized in Fig. 2a. In
total, 113 composition-determined compounds (CCDs) were
newly detected in rat plasma after maoto treatment. Of these,
19 were present in maoto extract, corresponding to 5.4% of the
352 CCDs originally present in maoto extract, while the other 94
CCDs were presumed to be metabolites generated from either
maoto compounds or endogenous substances because they were
not detected in maoto extract or control plasma.
The data from the LC-Orbitrap-MS analysis of maoto extract and
rat plasma after oral administration, including the percentage of
detected compounds, CCDs and chemical structure-determined
compounds, are summarized in Supplementary Table 2. The
chemical structure of only a small proportion of the CCDs, i.e., 88
of 352 CCDs in maoto extract and 22 of 89 CCDs in the rat plasma
at 1 h after administration (Supplementary Table 2), were
identiﬁed by using existing chemical databases.
Among the 113 compounds detected in rat plasma after maoto
administration, 19 were found in maoto extract (e.g., ephedrine,
methylephedrine, norephedrine, liquiritigenin, 5,6,7,8-tetrahydro-
lepidine, mandelonitrile, etc.) and 3 were maoto-derived metabo-
lites generated by rat and/or its enteric ﬂora (methylephedrine N-
oxide, hippuric acid and glycyrrhetinic acid). A further 35 CCDs
were host-derived endogenous metabolites (phospholipids and
acylcarnitines), whereas the source of the remaining 56 CCDs
could not be determined (Fig. 2a). The details of 35 endogenous
metabolites (28 phospholipids, 4 acylcarnitines, and 3 metabolites)
and the undetermined 56 CCDs are listed in Supplementary Fig. 2.
The arrangement of compounds detected by non-targeted
analysis in descending order from high to low peak intensity
showed a statistical long-tail distribution (Fig. 2b).
Plasma PK proﬁling of the major compounds of maoto
To supplement the non-targeted analysis, we performed a
targeted PK analysis of well-curated maoto compounds identiﬁed
through a literature search. We used the LC-MS/MS method and
simultaneously analyzed the PK proﬁles of 21 major compounds of
maoto after oral administration in rats (Supplementary Table 1). It
should be noted that, due to methodological limitations, some
well-known maoto compounds such as amygdalin, prunasin, and
cinnamic acid were not detected by non-targeted analysis in this
study (see Supplementary Methods). Of the 21 compounds, 19
were detected in the plasma of rats given maoto (2 g/kg)
(Supplementary Fig. 3), and 6 showed a relatively higher
concentration in plasma than the other compounds (Fig. 2c, d).
In terms of PK proﬁle, the following ﬁve compounds reached
relatively high concentrations within 1 h of administration (Tmax:
0.25–1.00 h), and were eliminated comparably from blood (t1/2:
0.937 ~ 6.58 h): ephedrines (ephedrine and pseudoephedrine)
from EH; amygdalin and its metabolite prunasin from AS; and
cinnamic acid, a metabolite of cinnamaldehyde from CC. The
maximum concentration of these compounds (Cmax) was 377, 163,
653, 2240, and 1280 ng/mL, respectively (Fig. 2c, d). On the other
hand, the concentration of glycyrrhetinic acid, an aglycon of
glycyrrhizin, which is a major compound in GR, gradually
increased and reached Cmax (373 ng/mL) 10 h after administration
(Fig. 2c, d; see Supplementary Fig. 3 for the proﬁles of the 19 major
compounds). The known metabolic pathways of the major
compounds detected are shown in Fig. 2e and Supplementary
Fig. 4.
Pharmacological proﬁling of maoto
We analyzed the effect of maoto and its constituent herbs on the
symptoms induced by administration of polyI:C, which causes
certain ﬂu-like symptoms, especially fever and fatigue in rats.
Administration of maoto (2 g/kg) suppressed the decrease in
locomotor activity and body weight induced by polyI:C injection
(Fig. 3a, b); however, it did not signiﬁcantly affect the reduced
food intake (Fig. 3c) or febrile response (Fig. 3d). On the other
hand, maoto administration in normal rats increased locomotor
activity and decreased food intake, but did not signiﬁcantly affect
body weight (Supplementary Fig. 5a–c).
A similar improvement in locomotor activity was observed after
administration of EH (Fig. 3a). Unlike maoto, however, adminis-
tration of extract from the individual herbs did not ameliorate the
body weight loss induced by polyI:C (Fig. 3b); and maoto analog,
comprising a mixture of three constituent herbs in maoto without
HE (AS, CC and GR; designated EH(−)-maoto) did not affect the
polyI:C-induced body weight loss and the decrease in locomotor
activity (Supplementary Fig. 6). These results indicated that neither
EH nor EH(−)-maoto could improve the body weight loss due to
polyI:C, suggesting that a combination of multiple herbs is
essential for this effect.
Among the cytokines upregulated by polyI:C, administration of
maoto (2 g/kg) signiﬁcantly attenuated the induction of tumor
necrosis factor (TNF)-α and interleukin (IL)-1β (Fig. 4a, b), as well as
interferon (IFN)-γ (Fig. 4c), whereas IL-6 remained unaffected (Fig.
Fig. 2 Proﬁles of compounds in maoto extract, and compound/metabolites detected in rat plasma after maoto administration. a1 Proﬁles of
compounds in maoto extract and those that speciﬁcally appeared/increased in rat plasma at 1 h and 8 h after maoto administration (2 g/kg).
The number of chemical composition-determined (CCD) compounds detected by non-targeted analysis in maoto extract (salmon pink), and
speciﬁcally in rat plasma at 1 h (blue) and 8 h (light green) after maoto administration are shown in the Venn diagram. a2 Of the 113 CCD
compounds detected in plasma, the proportions of original maoto compounds (salmon pink) and metabolites subcategorized as maoto-
derived metabolites (purple), endogenous metabolites (light blue), and undetermined compounds (mint green) are shown as a pie chart. a3
The chemical formulae and names of original maoto compounds and maoto-derived compounds are shown as color-coded graphs. b
Distribution of CCD compounds speciﬁcally detected in rat plasma by non-targeted analysis after maoto administration. The CCD compounds
are arranged in descending order from high to low peak intensity at 1 h and 8 h after maoto treatment. If the same CCD compounds were
detected at 1 h and 8 h after treatment, the higher intensity was used. c Targeted LC-MS/MS analysis of the PK properties of major maoto
compounds in plasma after maoto administration (2 g/kg). Among 21 major compounds that were measured, the PK properties of
compounds with relatively high concentrations in plasma are shown. The compounds derived from Ephedrae Herba (EH), Armeniacae Semen
(AS), Cinnamomi Cortex (CC) and Glycyrrhizae Radix (GR) are marked in red, blue, green and gray, respectively. Data represent mean± SD (n=
3 for each time point). d Plasma PK parameters of six major maoto compounds in plasma after oral administration of maoto (2 g/kg). e Major
metabolic reactions of original compounds in maoto detected by non-targeted analysis. Compounds detected in maoto extract and rat
plasma at 1 h and 8 h after maoto administration (2 g/kg) are shown as color-coded graphs (salmon pink, light blue, and mint green,
respectively). A single arrow indicates a compound metabolized in a single reaction; a series of three arrows indicates a compound
metabolized in a multistep reaction. Ephedrines (methylephedrine, ephedrine and pseudoephedrine) are metabolized to methylephedrine N-
oxide or hippuric acid, and cinnamic acid is metabolized to hippuric acid in organs such as the liver in vivo. Glycyrrhizin, a glycoside, is
metabolized to an aglycon (glycyrrhetinic acid) by glucuronidase of Enterobacteria
Compound and pharmacological proﬁling of maoto
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4d). By contrast, IL-10 induction was signiﬁcantly enhanced (Fig.
4e). The effect of maoto on TNF-α and IL-10 was conﬁrmed at
lower doses of 0.25 and 0.5 g/kg (Supplementary Fig. 7a, b).
Metabolomic proﬁling of maoto by GC-MS/MS
Next, we carried out metabolomic analysis after maoto adminis-
tration by using GC-MS/MS as shown in Fig. 5 and Supplementary
Table 3. The metabolites of tricarboxylic acid (TCA) cycle were
downregulated and those of pentose phosphate pathway (PPP)
were upregulated in the plasma of polyI:C-treated rats. In addition,
polyI:C consistently decreased norepinephrine and increased
adenosine.
Administration of maoto to polyI:C-treated or untreated rats
increased ketone bodies. Furthermore, maoto treatment led to a
decrease in amino acids, particularly those categorized as essential
amino acids and branched-chain amino acids (BCAAs), in both
normal and polyI:C-treated rats.
Metabolomic proﬁling of maoto by LC-MS/MS
Further metabolomic analysis of lipid mediators in the plasma 2 h
after treatment was conducted using LC-MS/MS (Fig. 6, Supple-
mentary Fig. 8 and Supplementary Table 4). The data showed that
polyI:C administration in normal rats mainly led to the upregula-
tion of metabolites of arachidonic acid (AA), such as prostaglan-
dins (PGs) and leukotrienes (LTs) (Fig. 6a). By contrast, maoto
administration in normal rats did not affect PGs, although it
signiﬁcantly decreased the metabolites of LTs, such as LTE4 and N-
acetyl-LTE4 (Fig. 6b). Maoto also increased several ω6 fatty acid
metabolites such as hydroxy-eicosatetraenoic acids (HETEs) and
dihydroxy-eicosatetraenoic acids (DHETs), which are alternative
metabolites generated from AA (Fig. 6b). Moreover, maoto
increased other ω-6 metabolites, including dihydroxyoctadecenoic
acids, which originate upstream of AA (Fig. 6b).
When maoto was administered to polyI:C-injected rats, the
opposing effects of polyI:C and maoto on the metabolic fate of AA
negated each other, resulting in no change in PGs and a moderate
increase in HETEs (Fig. 6c). Furthermore, maoto treatment
Fig. 3 Effects of maoto and its constituent herbs on polyI:C (PIC)-induced sickness phenotypes. a Percentage change in locomotor activity, b
changes in body weight, c changes in food intake, and d body temperature. The change in each group is relative to the value measured
immediately before maoto (MT) administration. PolyI:C was administered at a dose of 6mg/kg. Maoto was administered at a dose of 2 g/kg,
and its constituent herbs (Ephedrae Herba (EH), Armeniacae Semen (AS), Cinnamomi Cortex (CC), and Glycyrrhizae Radix (GR)) were
administered at doses equivalent to their respective content in 2 g/kg of maoto (EH, 645mg/kg; AS, 645mg/kg; CC, 516mg/kg; GR, 194mg/
kg). Data represent mean± SEM of the following measurements: a, b, and c, Control (n= 19), PIC (n= 23), PIC +MT (n= 23), PIC + EH (n= 18),
PIC + CC (n= 23), PIC + AS (19) and PIC + GR (19); d, n= 10. **P< 0.01 versus control group; ++P< 0.01, +P< 0.05 versus polyI:C group by Welch’s
t-test with Bonferroni correction
Compound and pharmacological proﬁling of maoto
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increased plasma ω3 fatty acids metabolites such as eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), as well as
their metabolites (Fig. 6b). Considering the metabolic enzymes
associated with each metabolite, polyI:C seemed to increase AA
metabolites that are generated by cyclooxygenases (COXs) and
lipoxygenases (LOXs), whereas maoto increased metabolites
generated by cytochrome P450s (CYPs), as shown in Fig. 6d.
We carried out a cluster analysis of fatty acid metabolites at 2 h
and 4 h after administration of polyI:C and maoto (Supplementary
Fig. 8). At 4 h after administration, many AA-derived eicosanoid
metabolites also increased in polyI:C-treated rats, although the
types of metabolites that were increased differed substantially as
compared with 2 h. By contrast, maoto administration to both
polyI:C-treated and untreated rats led to a decrease in almost all
eicosanoid metabolites.
Lastly, to clarify the global changes in lipid metabolites, we
grouped the bioactive lipids based on their proinﬂammatory or
anti-inﬂammatory properties and calculated the proinﬂammatory
and anti-inﬂammatory indices, as described by Tam et al.22 PolyI:C
injection led to a higher proinﬂammatory index at 2 h. At 4 h, both
the proinﬂammatory and anti-inﬂammatory indices were higher
than in the other groups, although the differences were not
statistically signiﬁcant. Maoto treatment in all groups resulted
in indices closer to 1, which represents the value of naïve rats
(Fig. 6e, f).
DISCUSSION
In the present study, compound proﬁling using experimentally
substantiated PK analyses and targeted/non-targeted
metabolomics conﬁrmed the presence of speciﬁc and well-
known major compounds in maoto. Ephedrines (ephedrine and
pseudoephedrine), amygdalin and its metabolite prunasin, cin-
namic acid, a metabolite of cinnamaldehyde, and glycyrrhetinic
acid, a metabolite of glycyrrhizin produced by gut microbiota,23
were detected in the plasma in appreciable amounts. Among
these compounds, ephedrines are known for their sympathomi-
metic effect.24,25 Ephedrines, amygdalin, and particularly glycyr-
rhetinic acid, have also been reported to possess various anti-
inﬂammatory effects.9,13,26 However, these constitute only a small
fraction of the original compounds in the maoto extract. Most of
the compounds in maoto were not detected in blood, at least in
their original forms. On the other hand, a considerable number of
maoto compounds were presumably converted to other forms by
enterobacteria and the xenobiotic system in the intestines and
liver in the host, before, during or after absorption, resulting in
compositional alteration over time.23 In this study, we detected
the compound proﬁle only in blood collected from the abdominal
inferior vena cava, which includes compounds degraded by liver.
It is important to consider the metabolism of maoto compounds
in the liver because it is involved in the excretion of maoto
compounds as xenobiotics and in the conversion of maoto
derived compounds to pharmacologically active compounds. Our
future studies will include metabolome analysis, non-target
analysis, and metabolism study of maoto components in the liver
tissue to reveal the pharmacological active compounds and PK/PD
interactions. To elucidate the absorption of maoto-derived
compounds, it will be necessary to compare compound proﬁles
among blood from the abdominal inferior vena cava, blood from
the portal vein, and urine.
Fig. 4 Effects of maoto on polyI:C (PIC)-induced cytokine response. Effect of maoto on polyI:C-induced cytokine levels: a TNF-α, b IL-1β, c IFN-
γ, d IL-6, and e IL-10. PolyI:C was administered at a dose of 6mg/kg. Maoto was administered at a dose of 2 g/kg. Relative plasma
concentrations of cytokines at 1, 2, 4, and 6 h after maoto administration were measured. Data represent mean± SEM of the following
measurements: at 1 h, n= 6; at 2 h, Control (n= 18), PIC (n= 18), Maoto (n= 17), PIC +Maoto (n-18); at 4 h, TNF-α (n= 10); IL-1β (n= 10), IL-10 (n
= 10), and IFN-γ (n= 10); at 4 h, Control (n= 9), PIC (n= 10), Maoto (n= 10), PIC +Maoto (n= 10); IL-6 (n= 10); at 6 h, n= 6. **P< 0.01; *P< 0.05
versus control group; ++P< 0.01, +P< 0.05 versus polyI:C group by Welch’s t-test with Bonferroni correction
Compound and pharmacological proﬁling of maoto
A Nishi et al.
6
npj Systems Biology and Applications (2017)  32 Published in partnership with the Systems Biology Institute
Non-targeted analysis is useful for studying compound proﬁles
in biological samples, but it also has several challenges. In this
study, for example, amygdalin was detected by targeted analysis
but not non-targeted analysis. However, we manually identiﬁed a
peak predicted to be amygdalin in the MS/MS spectrum that was
returned as an unknown peak for which the composition formula
could not be determined. It is likely that the composition formula
could not be calculated because evaluation of the adduct ion was
not successful. Improving the determination accuracy of com-
pound peaks is a future task for non-targeted analysis.
Our study also showed that endogenous metabolites had been
concomitantly produced by 1 h after maoto administration. Taken
together, our results imply that (1) the initial process of conversion
of herbal compounds induces metabolic perturbations within 1 h,
which might contribute to the initial physiological changes
induced by maoto; and (2) newly produced maoto-derived and
endogenous metabolites might potentiate and/or modify sub-
sequent pharmacological effects. Thus, a comprehensive elucida-
tion of serial plasma proﬁles of THM-derived and endogenous
metabolites after THM administration is essential for delineating
the mechanisms of action of THM. To aid this approach, however,
databases of metabolites, particularly metabolites of herbal
compounds produced by human and enteric microbiota should
be developed because here we could not determine the chemical
structures of many metabolites that were detected in blood after
maoto administration due to the lack of MS and MS/MS data for
such metabolites.
In the present study, using a polyI:C injection model, we
observed the beneﬁcial effect of maoto on fatigue symptoms, as
previously reported in clinical settings. The observed effects of
maoto on cytokines and ﬂu-like symptoms are in good agreement
with previous animal and clinical studies indicating that fatigue
Fig. 5 Heat map of changes in common metabolite levels in polyI:C-treated and/or maoto-treated rats. Heat map showing the fold change of
each common metabolite in plasma after administration of polyI:C in control (P/C), maoto in control (M/C), and maoto in polyI:C-treated (PM/
P) rats. Magenta indicates an increase in metabolite fold number or up-regulation; green indicates down-regulation of a speciﬁc metabolite
versus the control (n= 6). BCAA branched-chain amino acid, EAA essential amino acid, PPP pentose phosphate pathway, TCA tricarboxylic acid
Compound and pharmacological proﬁling of maoto
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symptoms are tightly regulated by proinﬂammatory cytokines,
particularly IL-1β.27–29 Furthermore, such modulatory effects of
maoto on proinﬂammatory and anti-inﬂammatory cytokines
might contribute to the reported beneﬁt of this medicine on
other disorders such as fever, arthralgia/myalgia, asthma, and
allergic symptoms in clinical settings.7,30,31 The effect of maoto on
these cytokines may be partially explained by the increase in some
of its major compounds/metabolites, such as ephedrines and EPA,
in plasma after administration. These compounds have been
reported to promote IL-10 secretion and inhibit proinﬂammatory
cytokines,13,32 although the detailed molecular mechanism
remains unclear.
The mechanism by which maoto attenuated the polyI:C-
induced production of PG/LT seems to differ from that of non-
steroidal anti-inﬂammatory drugs (NSAIDs). In normal rats, for
instance, maoto did not have a consistent effect on metabolites of
COXs and LOXs, whereas polyI:C upregulated metabolites of AA
such as PGs and LTs, which are related to the induction of pyretic
and inﬂammatory symptoms. COX products such as PGs did not
change, but TXB2 increased after maoto administration. Concern-
ing 5-LOX products, N-acetyl-LTE4 potently decreased, while 9S-
hydroperoxy-10E,12Z-octadecadienoic acid (9-HpODE) increased.
Recently, it was reported that individual NSAIDs have speciﬁc
effects on broad lipid mediators. For example, the serum
lipidomics of aspirin-treated and ibuprofen-treated patients
showed a consistent decrease in various COX and 5-LOX products,
including TXB2, whereas the effects on CYP products were
relatively moderate.33,34 In addition, it was noted that the effects
on 12-LOX and 15-LOX differed between aspirin and ibuprofen.
Our study data suggested that maoto activated certain metabolic
pathways, such as HETE and DHET biosynthesis, eventually leading
to a decrease in AA supply in the COX-related and/or 5-LOX-
related metabolic pathways (Fig. 6a, b, c, Supplementary Fig. 8 and
Supplementary Table 4). HpODE and DiOHM biosynthesis, which
Fig. 6 Proﬁle of lipid mediators after administration of polyI:C and/or maoto. Comparison of fold changes of lipid mediators in plasma after
administration of a polyI:C in control (PIC/Control(P/C)), bmaoto in control (Maoto/Control(M/C)), and cmaoto in polyI:C-treated (PIC +Maoto/
PIC(PM/P)) rats, shown as metabolic pathways of lipid mediators. These pathways indicate fatty acids and lipid mediators that increased or
decreased by > 0.38 or <−0.38 log fold change in response to each treatment, as well as key metabolites in the pathways. Circles indicate
metabolites; undetected metabolites are colored gray. Rectangles indicate enzymes (COX, CYP and LOX) involved in metabolizing the lipid
mediators. EPA and DHA are categorized as ω3 fatty acids; LA, DGLA, and AA are categorized as ω6 fatty acids. d Summary of changes in the
metabolic pathways of lipid mediators. Fisher’s exact test was used to assess the effects of each treatment on lipid mediators categorized by
the COX, CYP and LOX pathways (*P< 0.05). All detected lipid mediators metabolized by the COX, LOX, and CYP pathways were included in
the test, and metabolites that signiﬁcantly decreased or increased against each control group (P< 0.05 by Welch’s t-test) were analyzed. The
metabolites in each metabolic pathway that signiﬁcantly increased or decreased are listed in Supplementary Information. e Proinﬂammatory
index and f anti-inﬂammatory index calculated as described by Tam et al.22 with modiﬁcation. Detected lipid mediators were categorized by
proinﬂammatory or anti-inﬂammatory index as described in Supplementary Information. The score of each group was normalized to the score
of its own control group. Data represent mean± SEM of the following measurements: at 2 h, Control (n= 18), Maoto (n= 17), PIC (n= 17), PIC
+Maoto (n= 17); at 4 h, n= 10. *P< 0.05 versus control group by Welch’s t-test with Bonferroni correction
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originates from linoleic acid (LA), was also enhanced, possibly
reducing AA generation. In general, metabolites of ω-3 fatty acids
are known as anti-inﬂammatory mediators. DHA inhibits proin-
ﬂammatory cytokines, TNF-α and IL-6, and shows an anti-
inﬂammatory effect via G protein-coupled receptor 120.35 In
addition to the known anti-inﬂammatory properties of EPA and
DHA, some of the lipid mediators induced by maoto such as 14,15-
DHET and 20-HETE have been reported to exert anti-inﬂammatory
effects via the activation of peroxisome proliferator-activated
receptors.36–40 Thus, maoto seems to decrease PGs/LTs via
interference in multiple loci upstream of the PG/LT biosynthesis
pathway, and to exert its beneﬁcial effect on inﬂammatory
response by tilting the balance of AA metabolism toward DHET/
HETE synthesis and away from PG/LT synthesis.
It is unclear by which compounds and by which mechanisms
the profound and rapid (~2 h) effects of maoto on lipid mediator
metabolism are induced. Among the ingredients analyzed in the
present PK study, glycyrrhetinic acid is unlikely to be involved in
these effects because it was produced and absorbed relatively
slowly after maoto administration. Other maoto compounds such
as ephedrines, cinnamic acid and amygdalin were rapidly
absorbed, and therefore might be responsible for the effects on
lipid mediator metabolism. Accordingly, methylephedrine is
metabolized to ephedrine by CYP.41 Several compounds in GR
such as isoliquiritigenin affect CYP.42 The effects of maoto
compounds on various CYPs have scarcely been investigated,
and the CYPs involved in AA metabolism have not been fully
elucidated; however, it may be possible that the multifaceted
effects of maoto constituents on various CYPs affect AA
metabolism. Along this line, it should be noted that, although
many AA-derived eicosanoid metabolites increased in polyI:C-
treated rats, maoto administration led to a decrease in almost all
eicosanoid metabolites at 4 h. This suggests that the three major
metabolic pathways of eicosanoid biosynthesis were all down-
regulated by maoto. When we analyzed the effect of maoto on
innate metabolites by non-targeted analysis, several lysopho-
spholipids containing LA, α-LA, eicosadienoic acid and adrenic
acid as fatty acid were increased 1 h after maoto treatment.
Because lysophospholipids generally modulate the acute proin-
ﬂammatory cytokine response,43 these phospholipids might be
associated with modulation of the inﬂammatory response by
maoto. Furthermore, in the of proﬁling of lipid mediators after
maoto treatment, those downstream of the fatty acids detected in
non-targeted analysis were increased (Fig. 6 and Supplementary
Fig. 7). These results suggested that maoto affects the production
of lysophospholipids upstream of lipid mediators, and affects a
broad extent of lipid mediators. We have integrated these ﬁndings
into a hypothesis of the multiple modes of action of maoto in
Supplementary Fig. 1.
Furthermore, our analysis of common metabolites showed that
metabolites of the TCA cycle were downregulated and those of
PPP were upregulated in the plasma of polyI:C-treated rats. These
observations might partially reﬂect the changes in metabolic
status related to the accelerated proliferation of macrophages by
activation of TLR ligands.44 In addition, polyI:C consistently
decreased norepinephrine and increased adenosine. The increase
in adenosine is in line with previous studies reporting an increase
in circulating adenosine in TLR-mediated systemic
inﬂammation.45,46 Adenosine is a signaling molecule that med-
iates numerous anti-inﬂammatory effects47 and is the ﬁnal
product of adenosine triphosphate breakdown; therefore, its
presence might reﬂect both the onset of a negative feedback loop
to limit inﬂammatory response48 and enhanced extracellular
adenosine generation by ectoenzymes on the macrophage
surface. Furthermore, administration of maoto to both polyI:C-
treated and untreated rats increased ketone bodies, reﬂecting
beta-oxidation. These changes, along with a concomitant rapid
and transient increase in norepinephrine, are indicative of the
sympathomimetic effect of EH in maoto. Moreover, maoto
treatment led to a decrease in amino acids, including BCAAs,
particularly in polyI:C-treated rats. These changes in BCAA and
ketone bodies might signify altered energy metabolism because
these products might act as alternative energy sources under
limited glucose utilization.49–51 We also noted that maoto
suppressed body weight loss without restoring food intake.
While we observed a relevant effect of maoto on acute
inﬂammatory response in the study model, we also recognized
the limitations of this study in explaining the entire effect of
maoto. For instance, the antipyretic effect of maoto was not
conﬁrmed in the present polyI:C model, in contrast to the ﬁndings
of a study using an inﬂuenza virus infectious model,7 suggesting
that its antipyretic effect in an infectious model is not simply due
to the inhibition of inﬂammatory cytokines. Furthermore, the
beneﬁcial effects of maoto on body weight loss could not be
reproduced by any single herb treatment, although the improve-
ment in locomotor activity was fully achieved by EH, which might
be explained by the well-known sympathomimetic effect of
ephedrines.24,25 This suggests that some of the effects of maoto
require a combination of multiple herbs to act on multiple
regulatory mechanisms in complex biological networks to
produce an integrated effect at the level of the organism. To
tackle these challenges, the combinatorial effect of components/
compounds should be analyzed in several models, including
inﬂuenza infection models.
Concerning the combination effect of maoto, it should be noted
that the voluminous and diversiﬁed compounds in maoto, which
are distributed in a “long-tail” fashion, might be involved in its
unique pharmacological activities. A theoretical framework to
explain how the systematic control of complex biological
networks can be achieved via perturbations of long-tail compo-
nents is being proposed.52 We conjecture that the contribution of
each “tail” component (i.e., minor compound) might be small, but
the sum of their diverse contributions might amount to levels of
activity comparable to those of the head component (i.e., major
“active” compound). For instance, well-known compounds in
maoto, such as ephedrine, prunasin and glycyrrhetinic acid, are
considered to comprise the “head” components. Investigating the
potential contributions of “long-tail” components to the pharma-
cological effects of maoto relative to those of the “head”
components might be critically important for elucidating the
totality of the effects and mechanisms of maoto.
To address the combination effect of compounds, we would like
to point out the importance of possible inter-herbal interactions at
the stage of decoction and extraction.53 Because Kampo is not a
combination of individually prepared herbal extracts, but rather an
extract prepared from decocting a mixture of several raw herbs
together, the overall extraction efﬁciency and compounds
extracted from each herb are affected by the herbs that coexist
in the decoction and extraction solution.
Another interesting possibility suggested by this study is that
Kampo might exert its pharmacological activities by inducing
metabolic perturbations in the host. The extraordinary number of
compounds in Kampo might affect various sites and stages of the
host metabolic pathways. Csete and Doyle54 have pointed out that
the changes in host metabolism inevitably alter the context,
circumstances and operating conditions of signaling and execu-
tion systems consisting of transcription factors and various
modiﬁcations of signaling proteins. Thus, intervention at the level
of host metabolism, which changes the “metabolic landscape”
upon which the biological signaling systems exert their effect,
might form part of the mechanism of action of herbal medicines.
Regarding the safety of maoto, cardiovascular events due to
overdosing on ephedrine/ephedra herbs have been reported.55
Furthermore, while the detailed disposition and metabolism of
natural compounds remains unclear, as described above maoto
constituents possibly have profound effects on CYP450: for
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example, compounds in Glycyrrhizae radix are known to inhibit
CYP450 isoforms.42 Therefore, while the direct inhibition of
CYP450 isoforms by maoto administration has not been estab-
lished, we need to carefully consider its metabolic interactions.
Comprehensive proﬁling of herbal compounds is informative not
only for efﬁcacy but also for adverse events such as drug
interactions.
In conclusion, we have shown that the extensive alterations in
maoto compounds/metabolites before and after administration,
and the profound and broad inﬂuence on host metabolism, are
unequivocally relevant to its diverse pharmacological effects.
Extensive proﬁling of compounds, metabolites and biological
activities of THM and THM-treated hosts is thus a powerful and
indispensable means for clarifying the beneﬁcial effects and
mechanisms of action of THM.
METHODS
The detailed protocols of each experiment are available under the
“Supplementary Methods” section.
Maoto and constitutive herbs
Maoto is an extracted mixture of Ephedrae Herba (EH) (32.3%), Armeniacae
Semen (AS) (32.3%), Cinnamomi Cortex (CC) (25.8%), and Glycyrrhizae
Radix (GR) (9.6%). The dry powdered extracts of maoto (supplied as TJ-27)
and constituent herbs industrially produced by spray-drying were supplied
by Tsumura & CO. (Tokyo, Japan).
Proﬁling of compounds in maoto extract
Extracts of maoto and its constitutive herbs were analyzed by using LC-
Orbitrap-MS. To identify the compounds, the obtained peaks were
matched to reference peaks in public databases such as Human
metabolome database (http://www.hmdb.ca) and KNApSAcK (http://
kanaya.naist.jp/KNApSAcK/), as well as in-house databases of natural
compounds at Kazusa DNA institute and TSUMURA Research Laboratories.
Proﬁling of compounds in maoto and metabolites in rat plasma
after administration of maoto
Maoto (2 g/kg dissolved in distilled water) was orally administered to male
Sprague–Dawley (SD) rats, and whole blood was obtained from the
abdominal inferior vena cava. Plasma samples were analyzed by non-
targeted analysis using LC-Orbitrap-MS. The peaks of metabolites speciﬁc
to the plasma of maoto-administered rats were identiﬁed by comparison
to the spectra of control plasma. The chemical formulae and names of the
detected peaks were estimated by collation with the databases described
in the Supplementary Methods to identify their chemical compositions and
structures.
Analysis of PK properties of maoto-derived major compounds and
metabolites
The PK properties of maoto-derived major compounds and metabolites
after maoto administration (1, 2 and 4 g/kg) were determined by LC-MS/
MS (Supplementary Table 2).
Pharmacological proﬁling of maoto
The effects of maoto on polyI:C-induced acute inﬂammatory response and
sickness phenotypes (i.e., changes in locomotor activity, body weight, food
intake, and body temperature) were analyzed in male SD rats. Maoto (0.25,
0.5, 1.0, and 2.0 g/kg dissolved in distilled water) was orally administered
concurrently with an intraperitoneal injection of polyI:C (3 and 6mg/kg;
dissolved in saline). Distilled water and saline were administered as vehicle
to rats in each control group. The effects of maoto on polyI:C-induced
sickness phenotypes, including decreased locomotor activity, body weight
and food intake, as well as febrile response, were evaluated. Whole blood
was obtained from the abdominal inferior vena cava. Plasma cytokine
levels were measured by ELISA or multiplex immunoassay; common
metabolites and lipid mediators were analyzed by GC-MS/MS and LC-MS/
MS, respectively.
Pathway maps of lipid mediators were created by using CellDesigner
4.4 software (http://www.celldesigner.org). We evaluated the effects of the
treatments on speciﬁc lipid mediators and categorized them according to
COX, CYP and LOX pathways by Fisher’s exact test. The proinﬂammatory
and anti-inﬂammatory indices were analyzed as described by Tam et al.
with modiﬁcation.22
Data availability
Compound and metabolite data measured by LC-Orbitrap-MS were shown
in Supplementary Fig. 2a–c. Metabolome data measured by GC-MS/MS and
LC-MS/MS were shown in Supplementary Tables 3 and 4. Relevant
experimental data are available from the authors.
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